Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jane McKenzie
Institutions:
The University of Melbourne,
Duke University,
Peter MacCallum Cancer Centre,
Duke Medical Center,
Duke Cancer Institute
Observed institutions:
The University of Melbourne,
Duke University,
Walter and Eliza Hall Institute of Medical Research,
Peter MacCallum Cancer Centre,
Duke Medical Center,
Austin Health,
Duke Cancer Institute,
Peter MacCallum Cancer Foundation
show all 8
ORCID:
0000-0003-2126-2838
Observed ORCID:
0000-0003-2126-2838
OpenAlex ID:
A5007942670
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
2025
·
Bilal Ashraf
, Jane McKenzie
, et al.
·
Prostate Cancer and Prostatic Diseases
·
5
Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study
2025
·
Colin Williams
, Andrisha-Jade Inderjeeth
, et al.
·
Clinical Genitourinary Cancer
·
2
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer
2025
·
Jane McKenzie
, Vanessa Wong
, et al.
·
Clinical Colorectal Cancer
·
2
Practical Clinical Consultation Guide to Radioligand Therapy in Prostate Cancer
2026
·
Jane McKenzie
, Natalia Kovaleva
, et al.
·
European Urology Focus
·
1
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)
2026
·
Santosh Gupta
, Siyuan Guo
, et al.
·
Prostate Cancer and Prostatic Diseases
·
1
Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Tara A. Seibert
, Jane McKenzie
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Does cytoplasmic AR-V7 circulating tumor cell (CTC) detection add utility in predicting AR pathway inhibitor benefit in men with mCRPC? A retrospective analysis of the PROPHECY study.
2025
·
Santosh Gupta
, Susan Halabi
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Case of the month from the Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Australia: recurrent metastatic spermatocytic tumour successfully treated with salvage systemic chemotherapy
2024
·
Jane McKenzie
, Catherine Mitchell
, et al.
·
British Journal of Urology
·
1
PDF
Primary thoracic aorta angiosarcoma presenting with thromboembolism and progressive claudication despite anticoagulation
2024
·
Jane McKenzie
, Sarat Chander
, et al.
·
Journal of Medical Imaging and Radiation Oncology
·
1
Radiopharmaceutical Combination Therapies in Advanced Prostate Cancer
2026
·
Yang Wang
, Jane McKenzie
, et al.
·
Journal of Nuclear Medicine
Clinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancer
2026
·
Jane McKenzie
, Lauren Howard
, et al.
·
Prostate Cancer and Prostatic Diseases
PDF
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer
2026
·
Andrew Armstrong
, Tara Seibert
, et al.
·
Research Square
Pembrolizumab in metastatic hormone-sensitive prostate cancer: lessons from the negative KEYNOTE-991 trial
2026
·
Jane McKenzie
, Arun A. Azad
·
Translational Andrology and Urology
Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial
2025
·
Jane McKenzie
, Arun A. Azad
·
European Urology
Real-world induction targeted therapy (TT) with immune checkpoint inhibitor (ICI) therapy switch in BRAF -mutant metastatic melanoma.
2025
·
Jane McKenzie
, Nadav Harel
, et al.
·
Journal of Clinical Oncology
Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.
2025
·
Jane McKenzie
, Lauren Howard
, et al.
·
Journal of Clinical Oncology
Preventive medication deprescribing in advanced cancer patients approaching end of life
2025
·
Jane McKenzie
, Catherine Dunn
, et al.
·
Internal Medicine Journal
Australia and New Zealand (ANZ) outcomes of high-dose chemotherapy and stem cell transplantation for relapsed or refractory germ cell tumors (GCT) from 1999 to 2019: Multicenter registry-based study with ABMTRR.
2021
·
Elizabeth Anne Connolly
, Andrew James Weickhardt
, et al.
·
Journal of Clinical Oncology
Abstract 18508: Extubation Failure is Associated With Increased Mortality Following First Stage Single Ventricle Reconstruction
2016
·
Thomas Scodellaro
, Jane McKenzie
, et al.
·
Circulation
Show more works
View as search
Works count:
19
Citation count:
15
H-index:
2
I10-index:
Year
Topic
Type